Penumbra, Inc. has announced the completion of enrollment for the STORM-PE clinical trial, a groundbreaking study evaluating the efficacy of computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ combined with anticoagulation, compared to anticoagulation alone in treating acute intermediate-high risk pulmonary embolism. The trial enrolled 100 patients and aims to provide high-quality evidence on the role of CAVT in improving right heart function and clinical outcomes. The completion of enrollment marks a significant milestone in the trial, which is conducted in partnership with The PERT Consortium®. Results of the STORM-PE trial have not yet been presented. For further details, visit https://www.penumbrainc.com/storm-pe-trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.